Annual Net Income
-$444.04 M
-$48.14 M-12.16%
31 December 2023
Summary:
Iovance Biotherapeutics annual net profit is currently -$444.04 million, with the most recent change of -$48.14 million (-12.16%) on 31 December 2023. During the last 3 years, it has fallen by -$184.46 million (-71.06%). IOVA annual net income is now -2810260.76% below its all-time high of -$15.80 thousand, reached on 31 December 2009.IOVA Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Net Income
-$83.54 M
+$13.56 M+13.96%
30 September 2024
Summary:
Iovance Biotherapeutics quarterly net profit is currently -$83.54 million, with the most recent change of +$13.56 million (+13.96%) on 30 September 2024. Over the past year, it has increased by +$30.22 million (+26.56%). IOVA quarterly net income is now -2510.16% below its all-time high of $3.47 million, reached on 31 December 2012.IOVA Quarterly Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Net Income
-$410.00 M
+$30.22 M+6.86%
30 September 2024
Summary:
Iovance Biotherapeutics TTM net profit is currently -$410.00 million, with the most recent change of +$30.22 million (+6.86%) on 30 September 2024. Over the past year, it has increased by +$22.98 million (+5.31%). IOVA TTM net income is now -29003.56% below its all-time high of $1.42 million, reached on 31 March 2013.IOVA TTM Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IOVA Net Income Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -12.2% | +26.6% | +5.3% |
| 3 y3 years | -71.1% | +3.0% | -31.7% |
| 5 y5 years | -259.3% | -68.8% | -146.2% |
IOVA Net Income High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -71.1% | at low | at high | +28.2% | -31.7% | +8.8% |
| 5 y | 5 years | -259.3% | at low | -68.8% | +28.2% | -146.2% | +8.8% |
| alltime | all time | <-9999.0% | at low | -2510.2% | +28.2% | <-9999.0% | +8.8% |
Iovance Biotherapeutics Net Income History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$83.54 M(-14.0%) | -$410.00 M(-6.9%) |
| June 2024 | - | -$97.10 M(-14.1%) | -$440.22 M(-2.1%) |
| Mar 2024 | - | -$112.98 M(-2.9%) | -$449.64 M(+1.3%) |
| Dec 2023 | -$444.04 M(+12.2%) | -$116.38 M(+2.3%) | -$444.04 M(+2.6%) |
| Sept 2023 | - | -$113.76 M(+6.8%) | -$432.98 M(+3.4%) |
| June 2023 | - | -$106.53 M(-0.8%) | -$418.83 M(+1.7%) |
| Mar 2023 | - | -$107.37 M(+1.9%) | -$411.66 M(+4.0%) |
| Dec 2022 | -$395.89 M(+15.7%) | -$105.32 M(+5.7%) | -$395.89 M(+1.5%) |
| Sept 2022 | - | -$99.62 M(+0.3%) | -$389.90 M(+3.6%) |
| June 2022 | - | -$99.35 M(+8.5%) | -$376.41 M(+5.0%) |
| Mar 2022 | - | -$91.61 M(-7.8%) | -$358.41 M(+4.7%) |
| Dec 2021 | -$342.25 M(+31.8%) | -$99.33 M(+15.3%) | -$342.25 M(+9.9%) |
| Sept 2021 | - | -$86.12 M(+5.9%) | -$311.32 M(+9.7%) |
| June 2021 | - | -$81.35 M(+7.8%) | -$283.77 M(+6.9%) |
| Mar 2021 | - | -$75.45 M(+10.3%) | -$265.44 M(+2.3%) |
| Dec 2020 | -$259.58 M(+31.4%) | -$68.40 M(+16.8%) | -$259.58 M(+1.9%) |
| Sept 2020 | - | -$58.57 M(-7.1%) | -$254.75 M(+3.7%) |
| June 2020 | - | -$63.02 M(-9.5%) | -$245.67 M(+6.7%) |
| Mar 2020 | - | -$69.59 M(+9.5%) | -$230.20 M(+16.5%) |
| Dec 2019 | -$197.56 M(+59.9%) | -$63.57 M(+28.5%) | -$197.56 M(+18.6%) |
| Sept 2019 | - | -$49.49 M(+4.1%) | -$166.56 M(+10.4%) |
| June 2019 | - | -$47.55 M(+28.7%) | -$150.91 M(+12.6%) |
| Mar 2019 | - | -$36.95 M(+13.4%) | -$134.01 M(+8.4%) |
| Dec 2018 | -$123.58 M(+34.2%) | -$32.58 M(-3.7%) | -$123.58 M(+5.8%) |
| Sept 2018 | - | -$33.83 M(+10.3%) | -$116.86 M(+11.1%) |
| June 2018 | - | -$30.66 M(+15.6%) | -$105.18 M(+7.4%) |
| Mar 2018 | - | -$26.52 M(+2.6%) | -$97.89 M(+6.3%) |
| Dec 2017 | -$92.06 M(+74.1%) | -$25.85 M(+16.7%) | -$92.06 M(+12.4%) |
| Sept 2017 | - | -$22.15 M(-5.3%) | -$81.90 M(+4.3%) |
| June 2017 | - | -$23.38 M(+13.0%) | -$78.51 M(+17.7%) |
| Mar 2017 | - | -$20.68 M(+31.8%) | -$66.69 M(+26.1%) |
| Dec 2016 | -$52.89 M | -$15.69 M(-16.4%) | -$52.89 M(+16.1%) |
| Sept 2016 | - | -$18.76 M(+62.2%) | -$45.56 M(+32.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2016 | - | -$11.56 M(+68.0%) | -$34.44 M(+17.8%) |
| Mar 2016 | - | -$6.88 M(-17.7%) | -$29.25 M(+5.7%) |
| Dec 2015 | -$27.66 M(+129.8%) | -$8.36 M(+9.5%) | -$27.66 M(+14.5%) |
| Sept 2015 | - | -$7.63 M(+19.9%) | -$24.17 M(+25.0%) |
| June 2015 | - | -$6.37 M(+20.2%) | -$19.33 M(+28.2%) |
| Mar 2015 | - | -$5.30 M(+8.9%) | -$15.07 M(+25.2%) |
| Dec 2014 | -$12.04 M(-52.6%) | -$4.87 M(+73.9%) | -$12.03 M(-35.5%) |
| Sept 2014 | - | -$2.80 M(+32.6%) | -$18.66 M(-26.2%) |
| June 2014 | - | -$2.11 M(-6.6%) | -$25.28 M(-5.0%) |
| Mar 2014 | - | -$2.26 M(-80.3%) | -$26.60 M(+4.8%) |
| Dec 2013 | -$25.38 M(+667.4%) | -$11.50 M(+22.2%) | -$25.38 M(+143.6%) |
| Sept 2013 | - | -$9.41 M(+174.4%) | -$10.42 M(+518.9%) |
| June 2013 | - | -$3.43 M(+227.7%) | -$1.68 M(-218.7%) |
| Mar 2013 | - | -$1.05 M(-130.2%) | $1.42 M(-142.9%) |
| Dec 2012 | -$3.31 M(-87.1%) | $3.47 M(-614.3%) | -$3.31 M(-78.1%) |
| Sept 2012 | - | -$673.90 K(+105.9%) | -$15.13 M(-25.4%) |
| June 2012 | - | -$327.30 K(-94.3%) | -$20.27 M(-34.4%) |
| Mar 2012 | - | -$5.77 M(-30.9%) | -$30.90 M(+20.3%) |
| Dec 2011 | -$25.69 M(+1497.9%) | -$8.35 M(+43.5%) | -$25.69 M(+42.1%) |
| Sept 2011 | - | -$5.82 M(-46.9%) | -$18.08 M(+39.3%) |
| June 2011 | - | -$10.96 M(+1842.2%) | -$12.98 M(+516.7%) |
| Mar 2011 | - | -$564.30 K(-23.9%) | -$2.10 M(+30.9%) |
| Dec 2010 | -$1.61 M(>+9900.0%) | -$741.90 K(+3.9%) | -$1.61 M(+85.2%) |
| Sept 2010 | - | -$713.80 K(+743.7%) | -$868.40 K(+449.3%) |
| June 2010 | - | -$84.60 K(+25.0%) | -$158.10 K(+105.9%) |
| Mar 2010 | - | -$67.70 K(+2843.5%) | -$76.80 K(+389.2%) |
| Dec 2009 | -$15.80 K(-72.3%) | -$2300.00(-34.3%) | -$15.70 K(-43.3%) |
| Sept 2009 | - | -$3500.00(+6.1%) | -$27.70 K(+3.7%) |
| June 2009 | - | -$3300.00(-50.0%) | -$26.70 K(-30.5%) |
| Mar 2009 | - | -$6600.00(-53.8%) | -$38.40 K(-32.7%) |
| Dec 2008 | -$57.10 K | -$14.30 K(+472.0%) | -$57.10 K(+33.4%) |
| Sept 2008 | - | -$2500.00(-83.3%) | -$42.80 K(+6.2%) |
| June 2008 | - | -$15.00 K(-40.7%) | -$40.30 K(+59.3%) |
| Mar 2008 | - | -$25.30 K | -$25.30 K |
FAQ
- What is Iovance Biotherapeutics annual net profit?
- What is the all time high annual net income for Iovance Biotherapeutics?
- What is Iovance Biotherapeutics annual net income year-on-year change?
- What is Iovance Biotherapeutics quarterly net profit?
- What is the all time high quarterly net income for Iovance Biotherapeutics?
- What is Iovance Biotherapeutics quarterly net income year-on-year change?
- What is Iovance Biotherapeutics TTM net profit?
- What is the all time high TTM net income for Iovance Biotherapeutics?
- What is Iovance Biotherapeutics TTM net income year-on-year change?
What is Iovance Biotherapeutics annual net profit?
The current annual net income of IOVA is -$444.04 M
What is the all time high annual net income for Iovance Biotherapeutics?
Iovance Biotherapeutics all-time high annual net profit is -$15.80 K
What is Iovance Biotherapeutics annual net income year-on-year change?
Over the past year, IOVA annual net profit has changed by -$48.14 M (-12.16%)
What is Iovance Biotherapeutics quarterly net profit?
The current quarterly net income of IOVA is -$83.54 M
What is the all time high quarterly net income for Iovance Biotherapeutics?
Iovance Biotherapeutics all-time high quarterly net profit is $3.47 M
What is Iovance Biotherapeutics quarterly net income year-on-year change?
Over the past year, IOVA quarterly net profit has changed by +$30.22 M (+26.56%)
What is Iovance Biotherapeutics TTM net profit?
The current TTM net income of IOVA is -$410.00 M
What is the all time high TTM net income for Iovance Biotherapeutics?
Iovance Biotherapeutics all-time high TTM net profit is $1.42 M
What is Iovance Biotherapeutics TTM net income year-on-year change?
Over the past year, IOVA TTM net profit has changed by +$22.98 M (+5.31%)